- Intended Use
- MRA is very effective at removing mycoplasma from infected cell cultures. It shows strong anti-mycoplasma activity against many types of mycoplasma including Mycoplasma orale, M. arginini, M. hyorhinis and Acholeplasma laidlawii.
MRA is also suitable for use after the removal of mycoplasma, to prevent recontamination of the culture with the original mycoplasma, at preventative doses.
This product can also be used to prevent initial infection of cells in culture by mycoplasma.
MRA is non toxic, and will not interfere with the viability or function of cells in culture. It should be emphasised that MRA should not be used as a substitute for good cell culture techniques.
- Approx. Protein Concentrations
- Store at room temperature.
This product should be stored undiluted.
This product is photosensitive and should be protected from light.
- Guaranteed until date of expiry. Please see product label.
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of Mycoplasma Removal Agent
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Instructions For Use
- MRA is very easy to use, simply requiring incubation for a week after addition to cell cultures contaminated
Indications for Use:
1. Add MRA to cell cultures contaminated by mycoplasma at a concentration of 0.5 μg/ml and incubate
for a week.
2. For media replacement or culture transfer (passage), use a medium containing MRA at this same
3. Transfer the cell cultures several times without MRA and confirm that regrowth of the contaminating
mycoplasma has not occurred.
If there is a concern about the presence of mycoplasma in serum or trypsin, MRA can be added to the
media at a concentration of 0.5 μg/ml to prevent contamination of the cell cultures exposed to these
N.B. The recommended concentration for use is 0.5 μg/ml. The MRA concentration may be raised up to 1
μg/ml only when the recommended concentration is ineffective in removing the mycoplasma.
The cytotoxicity of MRA is low and cell toxicity is rare when used at the recommended concentration. For
specific function of any cell, however, it is recommended that the retention of desired cellular characteristics
be confirmed after treatment.
Please follow this link to view Sample Data.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
Product Specific References
References for Mycoplasma Removal Agent
Nakai, N. et al. (2000) Detection and elimination of contaminating microorganisms in transplantable tumors and cell lines.
Exp Anim. 49 (4): 309-13.
Ndungu, F.M. et al. (2006) CD4 T cells from malaria-nonexposed individuals respond to the CD36-Binding Domain of Plasmodium falciparum erythrocyte membrane protein-1 via an MHC class II-TCR-independent pathway.
J Immunol. 176 (9): 5504-12.
Chang, M.C. et al. (2015) N-Farnesyloxy-norcantharimide and N-farnesyl-norcantharimide inhibit the progression of leukemia and increase survival days in a syngeneic mouse leukemia model.
Anticancer Drugs. 26 (5): 508-17.
Entrican, G. et al. (2009) Growing Hybridomas
The Protein Protocols Handbook: 1887-99.
Molla Kazemiha, V. et al. (2009) PCR-based detection and eradication of mycoplasmal infections from various mammalian cell lines: a local experience.
Cytotechnology. 61 (3): 117-24.
Molla Kazemiha, V. et al. (2011) Efficiency of Plasmocin™ on various mammalian cell lines infected by mollicutes in comparison with commonly used antibiotics in cell culture: a local experience.
Cytotechnology. 63 (6): 609-20.